Andrew Barrett, Ph.D., appointed Vice President, Scientific Affairs
CORALVILLE, Iowa, June 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced an addition to its senior leadership team with the promotion of Dr. Andrew Barrett as Vice President, Scientific Affairs. Dr. Barrett has contributed to KemPharm’s scientific research and development since early 2016, playing a significant role in the clinical/regulatory development of KemPharm’s pipeline assets and communicating key scientific findings to the medical and investor communities.
As Vice President, Scientific Affairs, Dr. Barrett will be responsible for leading KemPharm’s medical communications strategies, while continuing to contribute to clinical/regulatory efforts. With nearly 20 years’ experience in academia and industry, Dr. Barrett is widely regarded as an expert in CNS pharmacology and therapeutics. Prior to joining KemPharm, Dr. Barrett held positions of increasing responsibility at Chimerix, Salix, Synchrony Healthcare, and Cephalon. He earned his Ph.D. in Neuroscience at University of North Carolina at Chapel Hill, and completed postdoctoral training at Harvard Medical School/McLean Hospital where he studied the abuse-related effects of stimulants and opioids.
“We are pleased to announce Andy’s formal promotion to KemPharm’s leadership team,” said Travis Mickle, Ph.D., KemPharm’s President and Chief Executive Officer. “Andy has been a key contributor and an invaluable resource to KemPharm since he joined us. This elevation further strengthens the management team at an important stage in our business evolution as we continue the development of our portfolio of prodrug product candidates and seek new opportunities to leverage our Ligand Activated Therapy (LAT) prodrug platform.”
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Caution Concerning Forward Looking Statements
This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: KemPharm's financial resources and whether they will be sufficient to meet KemPharm's business objectives and operational requirements; results of earlier studies and trials may not be predictive of future clinical trial results; the protection and market exclusivity provided by KemPharm's intellectual property; risks related to the drug discovery and the regulatory approval process; the impact of competitive products and technological changes; and the FDA approval process under the Section 505(b)(2) regulatory pathway, including without limitation any timelines for related approval. KemPharm's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning KemPharm’s business are described in additional detail in KemPharm's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, and KemPharm’s other Periodic and Current Reports filed with the Securities and Exchange Commission. KemPharm is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.